Advertisement

Annals of Hematology

, Volume 83, Issue 11, pp 691–695 | Cite as

Antiproliferation effects of oridonin on HL-60 cells

  • Jia-Jun LiuEmail author
  • Xin-Yao Wu
  • Jun Peng
  • Xiang-Lin Pan
  • Hui-Ling Lu
Original Article

Abstract

The antiproliferation effects and inhibition of telomerase activity of oridonin on leukemic HL-60 cells were studied. HL-60 cells in culture medium were treated with different concentrations of oridonin. The inhibitory rate of the cells was measured by MTT assay. Cell apoptotic rate was detected by flow cytometry (FCM). Morphology of cell apoptosis was observed by Wright’s stain. Reverse transcriptase polymerase chain reaction (RT-PCR) and PCR–enzyme-linked immunosorbent assay (ELISA) were used to detect hTERT mRNA expression and telomerase activity before and after apoptosis. Oridonin (over 8 μmol/l) could inhibit the growth of HL-60 cells and cause apoptosis significantly. The suppression was in both time-dependent and dose-dependent manner. Marked morphological changes of cell apoptosis including condensation of chromatin and nuclear fragmentation were observed clearly by Wright’s stain especially after the cells were treated 48–60 h by oridonin. The expression of hTERT mRNA as well as activity of telomerase were decreased concurrently by treatment with oridonin in HL-60 cells. Oridonin can downregulate the hTERT mRNA expression and decrease the telomerase activity of HL-60 cells; it has apparent antiproliferation and apoptosis-inducing effects on HL-60 cells in vitro.

Keywords

Oridonin Leukemia Telomerase Apoptosis 

References

  1. 1.
    Han QB, Li ML, Li SH et al (2003) Ent-kaurane diterpenoids from Isodon rubescens var. lushanensis. Chem Pharm Bull 51:790–793Google Scholar
  2. 2.
    Zhang JX, Han QB, Zhao AH, et al. (2003) Diterpenoids from Isodon japonica. Fitoterapia 74:435–438Google Scholar
  3. 3.
    Kezoe T, Chen SS, Tong XJ, et al. (2003) Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 23:1187–1189Google Scholar
  4. 4.
    Fletcher TM (2003) Telomere higher-order structure and genomic instability. IUBMB Life 55:443–449Google Scholar
  5. 5.
    Mokbel K (2003) The evolving role of telomerase inhibitors in the treatment of cancer. Curr Med Res Opin 19:470–472Google Scholar
  6. 6.
    Ohyashiki JH, Sashida G, Tauchi T, et al. (2002) Telomeres and telomerase in hematologic neoplasia. Oncogene 21:680–687Google Scholar
  7. 7.
    Jima A, Tauchi T, Sashida G, et al. (2003) Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia 17:560–567Google Scholar
  8. 8.
    Hu W, Kavanagh JJ (2003) Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4:721–729Google Scholar
  9. 9.
    Debatin KM (2004) Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 53:153–159Google Scholar
  10. 10.
    Liu WH, Hsu CY, Benjamin YM (1999) Nucleophosmin/B23 regulates the susceptibility of human leukemia HL-60 cells to sodium butyrate-induced apoptosis and inhibition of telomerase activity. Int J Cancer 83:765–771Google Scholar
  11. 11.
    Iida A, Yamaguchi A, Hirose K (2000) Telomerase activity in colorectal cancer and its relationship to bcl-2 expression. J Surg Oncol 73:219–223Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Jia-Jun Liu
    • 1
    Email author
  • Xin-Yao Wu
    • 2
  • Jun Peng
    • 3
  • Xiang-Lin Pan
    • 3
  • Hui-Ling Lu
    • 2
  1. 1.Department of HematologyThe Third Affiliated Hospital of Sun Yat-Sen UniversityGuangzhouPeople’s Republic of China
  2. 2.Department of Forensic BiologyMedical College of Sun Yat-Sen UniversityGuangzhouPeople’s Republic of China
  3. 3.Department of Hematology, Qilu HospitalShandong UniversityJinanPeople’s Republic of China

Personalised recommendations